GlaxoSmithKline Plc has acquired Swiss developer Okairos AG for $324 million and was an all-cash purchase. Okairos is a developer of vaccine technologies and GlaxoSmithKline hopes to expant its range of inoculations.
Included in the deal are early stage products targeting respiratory syncytial virus, hepatitis C, malaria, tuberculosis, ebola and HIV. GlaxoSmithKline is the U.K.'s biggest drugmaker and has said there are plans to use technology from Okairos, such as genetic material delivery via virus, to produce vaccines that prevent infections and fight diseases. Read the full story.